Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Disclosed holdings
$5.6M
1-day change
▲ 1.85%
Positions on file
1
issuers disclosed in Forms 3/4/5 and Schedules 13D/G

Disclosed holdings over time 53 weekly points

What the 1 currently disclosed position would have been worth at each week’s closing price. A rising line means the shares got more valuable, not that this person bought more.

How the line is built

Share counts are as last reported to the SEC and held constant; only prices move.

2025-09-05$4.0M – $7.3M2026-09-04

Insider activity Feb 14, 2022 – Feb 18, 2026

Gaurav Shah is recorded in filings to the U.S. SEC via EDGAR as officer and board member, and reported 17 transactions between Feb 14, 2022 and Feb 18, 2026. The buy and sell totals below count only codes P, S.

Why the other codes are excluded

Share awards (A), shares withheld to pay tax (F), option exercises (M) and gifts (G) also appear in the table, but they are consequences of a pay package or a private transfer, not a decision to buy or sell on the open market. Counting them would turn this into a compensation ranking.

Open-market buys (code P)
$101.6K
1 purchase on file priced rows only
Open-market sales (code S)
$841.9K
9 sales on file priced rows only
All reported transactions
17
every code, including awards and exercises
Pattern
Bought and sold in similar amounts
last 12 months of the window

Reported transactions

Price 0.00 is a real reported figure on gifts (G) and share awards (A) — not a missing number. The 23 most recent rows are grouped into 22 lines by date, company and transaction type — open a line to see every lot with its own source link.

How to read this list

Every row is one line of one Form 4 or Form 5, with the filing it came from. Where the record carries no price at all we leave the cell empty instead of guessing one.

The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.

  1. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 2,293 shares $7.8K at $3.38 SEC filing ↗
  2. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 2,837 shares $9.6K at $3.38 SEC filing ↗
  3. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 55,684 shares $172.1K at $3.09 SEC filing ↗
  4. ROCKET PHARMACEUTICALS, INC. RCKT M Option exercise or conversionnot a buy/sell decision 76,490 shares $129.3K at $1.69 SEC filing ↗
  5. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 2,409 shares $7.3K at $3.01 SEC filing ↗
  6. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 2,728 shares $9.8K at $3.61 SEC filing ↗
  7. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 5,990 shares $20.0K at $3.34 SEC filing ↗
  8. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 12,279 shares $40.6K at $3.31 SEC filing ↗
  9. ROCKET PHARMACEUTICALS, INC. RCKT A Grant or awardnot a buy/sell decisionreported at zero 286,028 shares $0 at $0.00 SEC filing ↗
  10. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 6,276 shares $18.7K at $2.98 SEC filing ↗
  11. ROCKET PHARMACEUTICALS, INC. RCKT F Shares withheld for taxesnot a buy/sell decision 2,234 shares $6.8K at $3.05 SEC filing ↗
  12. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 2,253 shares $14.5K at $6.45 SEC filing ↗
  13. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 3,621 shares $23.6K at $6.53 SEC filing ↗
  14. ROCKET PHARMACEUTICALS, INC. RCKT P Open-market purchase 20,000 shares $101.6K at $5.08 SEC filing ↗
  15. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 16,303 shares $172.5K at $10.58 SEC filing ↗
  16. ROCKET PHARMACEUTICALS, INC. RCKT A Grant or awardnot a buy/sell decisionreported at zero 81,655 shares $0 at $0.00 SEC filing ↗
  17. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 11,091 shares $144.7K at $13.05 SEC filing ↗
  18. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 9,650 shares $178.5K at $18.50 SEC filing ↗
  19. ROCKET PHARMACEUTICALS, INC. RCKT S Open-market sale 9,790 shares $228.6K at $23.35 SEC filing ↗
  20. ROCKET PHARMACEUTICALS, INC. RCKT M Option exercise or conversion × 2not a buy/sell decisionreported at zero 17,662 shares $0
    The 2 lots that make up this line, each with the source behind it.
    Shares Price Value Filing
    7,979 $0.00reported at zero $0 SEC filing ↗
    9,683 $0.00reported at zero $0 SEC filing ↗
  21. ROCKET PHARMACEUTICALS, INC. RCKT J Other acquisition or dispositionnot a buy/sell decisionreported at zero 67,785 shares $0 at $0.00 SEC filing ↗
  22. ROCKET PHARMACEUTICALS, INC. RCKT J Other acquisition or dispositionnot a buy/sell decisionreported at zero 23,940 shares $0 at $0.00 SEC filing ↗

Disclosed holdings

Shares is the amount on the form; value is that amount times the closing price shown. Rows with no closing price are left blank, so they may add up to less than the headline figure.

What is not counted here

Each row is one filing you can open. Private companies, real estate, bonds and crypto are not in SEC insider filings and are therefore not counted here.

Equity positions disclosed to the SEC, with the source filing behind each row.
Issuer Ticker Security Shares Close Value Form Reported Filing
ROCKET PHARMACEUTICALS, INC. RCKT Common Stock 1,452,293 $3.86 $5.6M 4 EDGAR ↗

Other insiders at the same companies

People who also file with the SEC at a company where Gaurav Shah reports shares.

Sharing a filing does not mean they work together day to day — it means both names appear on the same issuer’s insider record.

Sources

The filings linked in the tables above are the sources for every figure on this page.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Profile record last refreshed Sep 8, 2026.